A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours

BACKGROUND: This first-in-human, phase I clinical trial of p28 (NSC745104), a 28-amino-acid fragment of the cupredoxin azurin, investigated the safety, tolerability, pharmacokinetics and preliminary activity of p28 in patients with p53(+) metastatic solid tumours. METHODS: A total of 15 patients wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Warso, M A, Richards, J M, Mehta, D, Christov, K, Schaeffer, C, Rae Bressler, L, Yamada, T, Majumdar, D, Kennedy, S A, Beattie, C W, Das Gupta, T K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619084/
https://www.ncbi.nlm.nih.gov/pubmed/23449360
http://dx.doi.org/10.1038/bjc.2013.74

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619084/
https://www.ncbi.nlm.nih.gov/pubmed/23449360
http://dx.doi.org/10.1038/bjc.2013.74

Ejemplares similares